Dec 10, 2020
NCT04504825: Phase 3: Efficacy & Safety of CAEL-101 in Patients With Mayo Stage IIIb AL Amyloidosis
NCT04504825: Phase 3: A Study to Evaluate the Efficacy and Safety of CAEL-101 in Patients With Mayo Stage IIIb AL Amyloidosis...
201
Dec 10, 2017
NCT03218683: Phase 1/2: Study of AZD5991 Alone or with Venetoclax in Relapsed Hem Malignancies
NCT03218683: Phase 1/2: Study of AZD5991 Alone or in Combination With Venetoclax in Relapsed or Refractory Haematologic Malignancies....
89